AFPL-67. Zoledronic acid safety and efficacy over 5 years in post-menopausal osteoporosis (2007)
Devogelaer, J, Burckhardt, P, Meunier, P, Kaufman, J, Lippuner, K, Body, J, ...
Kanis, J.A., Oden, A., Johnell, O., Johansson, H., Laet, C. De, Brown, J., ...
BMD and clinical risk factors predict hip and other osteoporotic fractures. The combination of clinical risk factors and BMD provide higher specificity and sensitivity than either alone. Introduction...
Kanis, J.A., Oden, A., Johnell, O., Johansson, H., De Laet, C., Brown, J., ...
SUMMARY: BMD and clinical risk factors predict hip and other osteoporotic fractures. The combination of clinical risk factors and BMD provide higher specificity and sensitivity than either alone....
AFPL-67. Zoledronic acid safety and efficacy over 5 years in post-menopausal osteoporosis (2007)
DEVOGELAER, JP, BURCKHARDT, P, MEUNIER, P, Kaufman, Jean, LIPPUNER, K, BODY, JJ, ...
Zoledronic acid efficacy and safety over five years in postmenopausal osteoporosis (2007)
Devogelaer, J. P., Brown, J. P., Burckhardt, P., Meunier, P. J., Goemaere, S., Lippuner, K., ...
In a 5-year study involving 119 postmenopausal women, zoledronic acid 4 mg given once-yearly for 2, 3 or 5 years was well tolerated with no evidence of excessive bone turnover reduction or any safety...
Zoledronic acid safety and efficacy over 5 years in post-menopausal osteoporosis (2006)
DEVOGELAER, JP, BURCKHARDT, P, MEUNIER, P, Kaufman, Jean, LIPPUNER, K, BODY, JJ, ...
Zoledronic acid safety and efficacy over 5 years in postmenopausal osteoporosis (2006)
DEVOGELAER, JP, BURCKHARDT, P, MEUNIER, P, Kaufman, Jean, LIPPUNER, K, BODY, JJ, ...
Intravenous zoledronic acid in postmenopausal women with low bone mineral density. (2002)
REID, IR, BROWN, JP, BURCKHARDT, P, HOROWITZ, Z, RICHARDSON, P, TRECHSEL, U, ...
Pharmacokinetics of Pamidronate in Patients With Bone Metastases (1992)
Leyvraz, S., Hess, U., Flesch, G., Bauer, J., Hauffe, S., Ford, J. M., ...
Background: Pamidronate is a secondgeneration bisphosphonate used in the treatment of tumor-induced hypercalcemia and in the management of bone metastases from breast cancer, myeloma, or prostate...
Consensus development conference: Prophylaxis and treatment of osteoporosis (1991)
Bouillon, Roger; U0010150, Burckhardt, P, Christiansen, C, Fleisch, H. A, Fujita, T, Gennari, C, ...
Bone mineral content in cystic fibrosis patients: correlation with fat-free mass.
Salamoni, F, Roulet, M, Gudinchet, F, Pilet, M, Thiébaud, D, Burckhardt, P
OBJECTIVE: To assess the bone mineral content in well nourished patients with cystic fibrosis and to seek a correlation with fat-free mass. METHODS: Fourteen cystic fibrosis patients aged 6 to 20...